中国医疗企业归创通桥近日在香港联交所上市，募集资金约23.98亿港元。国浩律师事务所、达维律师事务所担任发行人律师；君合律师事务所、高伟绅律师事务所则为联席保荐人提供法律意见。

归创通桥是由归创医疗和通桥医疗2019年1月合并而成，是一家中国神经和外周血管介入医疗器械企业。此次上市之前，归创通桥于今年1月完成C+轮融资，合计融资7600万美元。

国浩团队由合伙人张小龙牵头领导；达维团队由合伙人褚洋、何鲤、王薛林牵头领导；高伟绅团队牵头合伙人则为方刘、向天宁。

该IPO的联席保荐人为摩根士丹利、中信证券。

Davis Polk and CC led on Chinese medical equipment maker’s Hong Kong IPO

Davis Polk & Wardwell and Grandall Law Firm have advised Chinese medical equipment maker Zylox-Tonbridge on its $330 million IPO in Hong Kong Stock Exchange, with Clifford Chance and JunHe advising the joint sponsors.

Established by the merger of Zylox Medical and Tonbridge Medical in January 2019, Zylox-Tonbridge makes and sells neuromedical and peripheral vascular intervention equipments. Prior to this IPO, the company has finished its $76 million C+ Series finance.

The Grandall team was led by partner Zhang Xiaolong. The Davis Polk team was led by partners Chu Yang, He Li and Steve Wang. The Clifford Chance team was led by partners Fang Liu and Xiang Tianning.

The joint sponsors were Morgan Stanley and CITIC Securities.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.